Panbela Therapeutics Inc.

IN THE PRESS

BioMidwest

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

January 16, 2024

·

5 min read

Deals

Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market

December 21, 2023

·

8 min read

BioMidwest

Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

December 18, 2023

·

8 min read

Drug Development

Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors

December 4, 2023

·

5 min read

Drug Development

Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification

November 29, 2023

·

6 min read

Business

Panbela Provides Business Update and Reports Q3 2023 Financial Results

November 9, 2023

·

13 min read

BioMidwest

Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market

November 3, 2023

·

9 min read

Drug Development

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

November 2, 2023

·

9 min read

BioMidwest

Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101

October 31, 2023

·

8 min read

BioMidwest

Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication

October 25, 2023

·

3 min read

JOBS